CRNX vs FBRX
CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors. FBRX: A clinical-stage biotech developing an anti-CD122 antibody (FB102) to modulate immune cells in autoimmune diseases, with promising early celiac disease data and trials underway in vitiligo and alopecia areata.
Side-by-side fundamentals
| Metric | CRNX | FBRX | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $83.92 | $76.83 | |
| Market cap as of 2026-08-08 | $8.8B | $1.1B | |
| PEG as of 2026-08-08 | -0.73 | n/a | |
| Net margin as of 2026-08-08 | -1189.9% | -158775.0% | CRNX higher |
| Gross margin as of 2026-08-08 | +86.0% | n/a | |
| Operating margin as of 2026-08-08 | -1302.5% | -150175.0% | CRNX higher |
| ROE as of 2026-08-08 | -44.2% | -106.2% | CRNX higher |
| ROA as of 2026-08-08 | -39.8% | -85.5% | CRNX higher |
| Debt / equity as of 2026-08-08 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-08 | n/a | -99.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -9.8% | |
| Beta as of 2026-08-08 | 0.02 | 2.28 | |
| 1-year return as of 2026-08-06 close | +194.1% | +626.2% | FBRX higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.